Edge Wealth Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Edge Wealth Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-35,000	Closed	-$448K	–	87
2022 Q3	$448K	Hold	35,000	–	–	0.1%	55
2022 Q2	$370K	Hold	35,000	–	–	0.08%	59
2022 Q1	$569K	Hold	35,000	–	–	0.11%	57
2021 Q4	$485K	Buy	35,000 +10,000	+40%	+$132K	0.09%	67
2021 Q3	$359K	Sell	25,000 -25,000	-50%	-$394K	0.07%	76
2021 Q2	$794K	Hold	50,000	–	–	0.16%	58
2021 Q1	$509K	Sell	50,000 -60,010	-55%	-$619K	0.11%	66
2020 Q4	$822K	Sell	110,010 -111,619	-50%	-$575K	0.19%	58
2020 Q3	$761K	Buy	221,629 +35,700	+19%	+$153K	0.18%	61
2020 Q2	$886K	Buy	+185,929	New	+$743K	0.17%	73

Other funds holding BCRX

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Edge Wealth Management's BCRX Position: Q4 2022 in Review

Edge Wealth Management sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2022, closing a stake of 35,000 shares — an estimated $448K sold.

Edge Wealth Management first reported a position in BCRX in Q2 2020 and held it in 10 quarters. The position peaked at $886K in Q2 2020. 230 funds tracked by Wall St. Rank hold BCRX as of Q4 2022.

Edge Wealth Management reported no remaining BioCryst Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Edge Wealth Management sold 35,000 BioCryst Pharmaceuticals shares in Q4 2022, an estimated $448K.
Edge Wealth Management first reported a position in BioCryst Pharmaceuticals in Q2 2020 and held it in 10 quarters.
Edge Wealth Management's BioCryst Pharmaceuticals position peaked at $886K in Q2 2020.
230 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2022.

Based on Edge Wealth Management's 13F filing for Q4 2022, filed 25 Jan 2023.